A Phase 2 interventional study of Vamorolone and Placebo in Becker Muscular Dystrophy, sponsored by ReveraGen BioPharma, Inc.. Completed at 2 sites in 2 countries. Open to male participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by ReveraGen BioPharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.
Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 62nd largest by enrollment of the 171 interventional ones that give a count, is one of 15 that started in 2022, is one of 57 in phase 2, and was the 176th registered.
481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
University of Florida · Sites in United States
Ages 6+ · Men only
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
University of Rochester · Sites in United States
Ages 0 days–3 yrs · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 64 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 57 · Phase 2 90 · Phase 3 40 · Phase 4 5
First in 2000; this study’s year is marked. 15 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is above the median of 26 across 332 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 25 across the 171 interventional studies, 75 across the 55 observational. Of the 160 that completed or were terminated, 78 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 232 have an industry lead sponsor. The 10 most frequent:
ReveraGen BioPharma, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
ReveraGen BioPharma, Inc. has 5 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
20 of the studies in Muscular Dystrophy, Duchenne with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT06290713University of FloridaVasodilator and Exercise Study for DMD (VASO-REx) | 2026-11 |
| NCT06450639Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | 2026-11-18 |
| NCT03368742Solid Biosciences Inc.Microdystrophin Gene Transfer Study in Adolescents and Children With DMD | 2026-11-30 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 20 to your calendar (.ics) → With an account.
Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase II pilot study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, PD, and exploratory clinical efficacy of vamorolone 500mg (250mg for body weight \<50 kg) daily administered orally compared to placebo over a treatment period of 24 weeks in males with BMD.
Funding Source - FDA OOPD
This Phase II pilot study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, PD, and exploratory clinical efficacy of vamorolone 500mg (250mg for body weight \<50 kg) daily administered orally compared to placebo over a treatment period of 24 weeks in males with BMD.
The study is comprised of a Pretreatment Screening Period of up to 5 weeks duration (unless extended to accommodate varicella vaccination), a 1-day Pretreatment Baseline Period, a 24-week Treatment Period, and a 4-week Dose-tapering Period (for subjects not continuing directly with further vamorolone treatment). Subjects will be enrolled into this study at the time written informed consent is given, and administered study medication only after completion of all Pretreatment Screening assessments to confirm eligibility.
Subjects will be assessed for safety, tolerability, PK, PD, and effect on physical functioning at scheduled visits throughout the study. Screening assessments will be performed prior to baseline assessments on Day -1 and first administration of study medication on Day 1.
After completion of Screening and Baseline assessments, subjects will return to the study clinic on Day 1 for safety, PK and PD assessments prior to administration of the first dose of study medication. Additional on-site study visits will occur at Week 4, Week 12, and Week 24. Adverse events, including serious adverse events (SAEs), and concomitant medications will be recorded throughout the study. A Data and Safety Monitoring Board (DSMB) will review SAEs and other pertinent safety data at regular intervals during the study, and make recommendations to the Sponsor and Study Team regarding study conduct.
Subject diaries will be dispensed at the Day 1, Week 12, and Week 24 (for subjects participating in the Dose-tapering Period) Visits to record AEs, changes to concomitant medications taken during the study, and any missed or incomplete doses of study medication.
The scheduled Week 12 and Week 24 assessments may be performed over a 2-day period, if necessary, to facilitate scheduling.
Subjects who complete the VBP15-BMD-001 study assessments through the Week 24 Visit may be given the opportunity to continue to receive vamorolone as part of an expanded access or compassionate use program.
Subjects who complete the VBP15-BMD-001 study and will enroll directly into an expanded access or compassionate use program to continue vamorolone treatment will be discharged from the VBP15-BMD-001 study following completion of all Week 24 assessments. Subjects who will not continue vamorolone treatment in the expanded access or compassionate use program will have their study medication dose tapered during a 4-week Dose-tapering Period to taper study medication prior to discharge from the study. For these subjects, site study staff will contact the subject or parent(s)/guardian(s) by telephone at Week 26 to ensure that the dose tapering is proceeding according to protocol, to assess potential signs or symptoms of adrenal suppression, and to address any questions the subject or parent(s)/guardian(s) may have.
In the event that any clinical or laboratory parameters remain abnormal at the time of discharge from the study, the subject will be followed medically, as clinically indicated.
Any subject who discontinues the study prior to the Week 24 Visit should return to the study unit for scheduled Week 24 assessments at the time of early withdrawal and a Week 28 Visit following the taper, whenever possible, assuming the subject has not withdrawn consent. Any subject who withdraws early from the study after study medication dosing has begun should undergo dose-tapering following early completion of the Week 24 assessments and a Week 28 Visit following the taper.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject is a male and has a confirmed diagnosis of Becker dystrophy as defined as:
Subject has evidence of chicken pox immunity as determined by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be randomized to one of two treatment groups in a 1:2 ratio (placebo:vamorolone).
Drug: Vamorolone
Subjects will be randomized to one of two treatment groups in a 1:2 ratio (placebo:vamorolone).
Drug: Placebo
Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
Also known as: VBP15
Placebo to Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
Also known as: Placebo to vamorolone
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 5.0
Clinical AEs and clinical laboratory AEs will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 Dose-limiting toxicities will be defined as follows: 1. The presence of a CTCAE Grade ≥ 3 AE, considered to be probably or definitely related to study drug 2. The presence of a CTCAE Grade ≥ 3 clinical laboratory AE considered to be probably or definitely related to study drug 3. Deterioration of the muscle condition, unexpected for the natural course of BMD and without other clear cause
Time frame: 24 weeks
Total Number of Adverse Events as Assessed by CTCAE Version 5.0
Clinical AEs and clinical laboratory AEs will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 Dose-limiting toxicities will be defined as follows: 1. The presence of a CTCAE Grade ≥ 3 AE, considered to be probably or definitely related to study drug 2. The presence of a CTCAE Grade ≥ 3 clinical laboratory AE considered to be probably or definitely related to study drug 3. Deterioration of the muscle condition, unexpected for the natural course of BMD and without other clear cause
Time frame: 24 weeks
Pharmacokinetics as Measured by Cmax
Blood will be collected from all subjects at the Day 1 Visit, at 1, 2 and 3 hours post-dose, for vamorolone PK analysis
Time frame: Day 1
Pharmacokinetics as Measured by Tmax
Blood will be collected from all subjects at the Day 1 Visit, at 1, 2 and 3 hours post-dose, for vamorolone PK analysis
Time frame: Day 1
Pharmacokinetics as Measured by Dose-normalized Cmax
Blood will be collected from all subjects at the Day 1 Visit, at 1, 2 and 3 hours post-dose, for vamorolone PK analysis
Time frame: Day 1
Safety as Measured by Serum Concentration of Osteocalcin
Change from baseline to Week 24 will be assessed for each treatment group.
Time frame: Week 24
Safety as Measured by Serum Concentration of Hemoglobin A1c (HbA1c)
Change from baseline to Week 24 will be assessed for each treatment group.
Time frame: Week 24
Safety as Measured by Fasting Serum Concentration of Glucose
Change from baseline to week 24 for each treatment group.
Time frame: Week 24
Safety as Measured by Fasting Serum Concentration of Insulin
Change from baseline to week 24 for each treatment group.
Time frame: Week 24
Safety as Measured by Concentration of Salivary Cortisol
First-in-morning salivary cortisol levels will be measured. Cortisol measures falling below 3.6 µg/dL (or 100 nM) will be considered to be indicative of the development of adrenal suppression. Cortisol will be assessed for each treatment group.
Time frame: Week 24
Efficacy as Measured by Concentration of Serum Pharmacodynamic Biomarkers (CD23)
CD23 (also known as Fc epsilon RII) concentration at Week 24.
Time frame: Week 24
Efficacy as Measured by Concentration of Serum Pharmacodynamic Biomarkers (MDC)
MDC (macrophage-derived chemokine) concentration at Week 24.
Time frame: Week 24
Efficacy as Measured by Time to Run/Walk Velocity (TTRWV)
Change from baseline to week 24 for each treatment group.
Time frame: Week 24
Efficacy as Measured by North Star Ambulatory Assessment (NSAA) Score
North Star Ambulatory Assessment (NSAA). The assessment's score can range from 0 to 34. Higher scores indicate a better outcome assessing functional mobility. Data is presented as change from baseline to week 24 for each treatment group.
Time frame: Week 24
| Milestone | Vamorolone | Placebo |
|---|---|---|
| Started | 26 | 13 |
| Completed | 26 | 13 |
| Not completed | 0 | 0 |
Clinical AEs and clinical laboratory AEs will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 Dose-limiting toxicities will be defined as follows: 1. The presence of a CTCAE Grade ≥ 3 AE, considered to be probably or definitely related to study drug 2. The presence of a CTCAE Grade ≥ 3 clinical laboratory AE considered to be probably or definitely related to study drug 3. Deterioration of the muscle condition, unexpected for the natural course of BMD and without other clear cause
| Participants | Vamorolone 500mg/Day [250mg if <50kg Body Weight] | Placebo |
|---|---|---|
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 5.0 | 17 | 10 |
Blood will be collected from all subjects at the Day 1 Visit, at 1, 2 and 3 hours post-dose, for vamorolone PK analysis
| ng/ml | Vamorolone (250mg) | Vamorolone (500mg) |
|---|---|---|
| Pharmacokinetics as Measured by Cmax | 860 ± 0 | 1045.70 ± 53.5 |
Blood will be collected from all subjects at the Day 1 Visit, at 1, 2 and 3 hours post-dose, for vamorolone PK analysis
| hours | Vamorolone (250mg) | Vamorolone (500mg) |
|---|---|---|
| Pharmacokinetics as Measured by Tmax | 2.95 ± 0 | 2.07 (0.97 to 3.02) |
Blood will be collected from all subjects at the Day 1 Visit, at 1, 2 and 3 hours post-dose, for vamorolone PK analysis
| ng/ml/mg | Vamorolone (250mg) | Vamorolone (500mg) |
|---|---|---|
| Pharmacokinetics as Measured by Dose-normalized Cmax | 1.7 ± 0 | 2.1 ± 53.5 |
Change from baseline to Week 24 will be assessed for each treatment group.
| ng/ml | Vamorolone 500mg/Day [250mg if <50kg Body Weight] | Placebo |
|---|---|---|
| Safety as Measured by Serum Concentration of Osteocalcin | -0.54 ± 5.502 | -0.98 ± 3.505 |
Change from baseline to Week 24 will be assessed for each treatment group.
| % NGSP | Vamorolone 500mg/Day [250mg if <50kg Body Weight] | Placebo |
|---|---|---|
| Safety as Measured by Serum Concentration of Hemoglobin A1c (HbA1c) | 0.13 ± 0.272 | -0.02 ± 0.259 |
Change from baseline to week 24 for each treatment group.
| mg/ml | Vamorolone 500mg/Day [250mg if <50kg Body Weight] | Placebo |
|---|---|---|
| Safety as Measured by Fasting Serum Concentration of Glucose | -10.911 ± 8.8944 | -2.284 ± 5.9165 |
Change from baseline to week 24 for each treatment group.
| mU/L | Vamorolone 500mg/Day [250mg if <50kg Body Weight] | Placebo |
|---|---|---|
| Safety as Measured by Fasting Serum Concentration of Insulin | 2.11 ± 9.962 | -3.63 ± 17.092 |
First-in-morning salivary cortisol levels will be measured. Cortisol measures falling below 3.6 µg/dL (or 100 nM) will be considered to be indicative of the development of adrenal suppression. Cortisol will be assessed for each treatment group.
| nmol/L | Vamorolone 500mg/Day [250mg if <50kg Body Weight] | Placebo |
|---|---|---|
| Safety as Measured by Concentration of Salivary Cortisol | 1.17 ± 0.91 | 8.80 ± 6.18 |
CD23 (also known as Fc epsilon RII) concentration at Week 24.
| pg/ml | Vamorolone 500mg/Day [250mg if <50kg Body Weight] | Placebo |
|---|---|---|
| Efficacy as Measured by Concentration of Serum Pharmacodynamic Biomarkers (CD23) | 2507.17 ± 960.23 | 2566.27 ± 805.15 |
MDC (macrophage-derived chemokine) concentration at Week 24.
| pg/ml | Vamorolone 500mg/Day [250mg if <50kg Body Weight] | Placebo |
|---|---|---|
| Efficacy as Measured by Concentration of Serum Pharmacodynamic Biomarkers (MDC) | 447.11 ± 112.01 | 562.99 ± 179.04 |
Clinical AEs and clinical laboratory AEs will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 Dose-limiting toxicities will be defined as follows: 1. The presence of a CTCAE Grade ≥ 3 AE, considered to be probably or definitely related to study drug 2. The presence of a CTCAE Grade ≥ 3 clinical laboratory AE considered to be probably or definitely related to study drug 3. Deterioration of the muscle condition, unexpected for the natural course of BMD and without other clear cause
| Events | Vamorolone 500mg/Day [250mg if <50kg Body Weight] | Placebo |
|---|---|---|
| Total Number of Adverse Events as Assessed by CTCAE Version 5.0 | 43 | 25 |
Change from baseline to week 24 for each treatment group.
| meters/second | Vamorolone 500mg/Day [250mg if <50kg Body Weight] | Placebo |
|---|---|---|
| Efficacy as Measured by Time to Run/Walk Velocity (TTRWV) | -0.05 ± 0.272 | -0.05 ± 0.164 |
North Star Ambulatory Assessment (NSAA). The assessment's score can range from 0 to 34. Higher scores indicate a better outcome assessing functional mobility. Data is presented as change from baseline to week 24 for each treatment group.
| Units on a scale | Vamorolone 500mg/Day [250mg if <50kg Body Weight] | Placebo |
|---|---|---|
| Efficacy as Measured by North Star Ambulatory Assessment (NSAA) Score | 0.16 ± 1.599 | 0.00 ± 1.706 |
Collected over From enrollment until end of follow-up, up to 28 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vamorolone 500mg/Day [250mg if <50kg Body Weight] | 0/26 (0%) | 1/26 (3.8%) | 13/26 (50%) |
| Placebo | 0/13 (0%) | 0/13 (0%) | 10/13 (76.9%) |
| Event | Vamorolone 500mg/Day [250mg if <50kg Body Weight] | Placebo |
|---|---|---|
| Gastroesophageal reflux diseaseGastrointestinal disorders | 1/26 | 0/13 |
| Event | Vamorolone 500mg/Day [250mg if <50kg Body Weight] | Placebo |
|---|---|---|
| FallInjury, poisoning and procedural complications | 2/26 | 5/13 |
| Upper respiratory tract infectionInfections and infestations | 1/26 | 2/13 |
| Back painMusculoskeletal and connective tissue disorders | 2/26 | 0/13 |
| COVID-19Infections and infestations | 1/26 | 1/13 |
| Foot fractureInjury, poisoning and procedural complications | 1/26 | 1/13 |
| HypertriglyceridemiaMetabolism and nutrition disorders | 2/26 | 0/13 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 2/26 | 0/13 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/26 | 1/13 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/26 | 1/13 |
| RashSkin and subcutaneous tissue disorders | 1/26 | 1/13 |
| Age, Categorical(Participants) | Vamorolone | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 26 | 13 | 39 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Vamorolone | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 26 | 13 | 39 |
| Race (NIH/OMB)(Participants) | Vamorolone | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 23 | 11 | 34 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Vamorolone | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 26 | 12 | 38 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2022 to primary completion in Aug 2025, 37 months.
Results were first posted in Sep 2026, 1 year after primary completion.
Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 37 months is above that.
Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vamorolone
Muscular Dystrophy, Duchenne →
ReveraGen BioPharma, Inc.